FDA (CDER)
GUIDANCE FINAL
Submitting Next-Generation Sequencing Data to the Division of Antiviral Products
Published: 7/1/2026Detected: 7/1/2026
Summary preview
Submits next-generation sequencing (NGS) data to the FDA’s Division of Antiviral Products using an expected data submission structure and review-ready formats to support consistent scientific evaluation.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
manufacturing
quality
clinical
safety
labeling
#next-generation sequencing
#NGS data submission
#antiviral products
#bioinformatics
#variant analysis
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
- Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
- Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
- Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026